In colorectal cancer (CRC), where early detection significantly improves outcomes, CRISPR‐Cas9 shows promise in identifying key gene mutations (e.g., PIC3C3A, KRAS, TP53, SMAD4, APC) in CRC organoids and detecting de novo driver genes. This evidence concerns the gene TP53 and colorectal carcinoma.